BRIEF—Novo Nordisk to spend $117 million on production site revamp

Danish diabetes giant Novo Nordisk has announced plans to invest 800 million Danish krone ($117) in the upgrading and expansion of its production facilities in Kalundborg, Denmark.

These facilities currently manufacture a range of products for diabetes and will be rebuilt and expanded to allow for future production of these products as well as new products to treat the disease. The work is expected to be completed by 2022.

Michael Hallgren, senior vice president for Novo Nordisk production in Kalundborg, said: “This investment in our production facilities highlights our ambition to continue strengthening our presence in Denmark and Kalundborg.

“Today, we manufacture around half of the world’s insulin in Kalundborg where we have been present for 50 years. Since the turn of the millennium alone, we have invested more than 16 billion Danish krone in these facilities, which are a cornerstone of our global production network.”